February 14th 2025
Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Surgeons Discuss Patient Selection Criteria for Breast Conservation
June 1st 1995BOSTON--Radical mastectomy is no longer routine for women with breast cancer, but the indications for breast conservation are still being debated by surgeons who fear the risk of breast cancer recurrence. At the 48th Annual Cancer Symposium, sponsored by the Society of Surgical Oncologists, a panel of physicians discussed patient selection criteria for breast conservation surgery.
Margin Status Predicts Local Recurrence After Lumpectomy
May 1st 1995SAN ANTONIO--Final excisional margin status proved to be the strongest predictor of local recurrence in a study of more than 300 breast cancer patients treated with breast-conserving surgery and radiation, Melanie C. Smitt, MD, said at the opening general session of the San Antonio Breast Cancer Symposium.
Flaxseed May Interfere With Estrogen Synthesis, Lower Risk of Breast Cancer
May 1st 1995TORONTO, Canada--Researchers have discovered that a high-fiber grain cultivated since the times of the ancient Egyptians may delay the growth of cancerous tumors. In studies conducted on rats, Lilian Thompson, PhD, of the University of Toronto, found that a component isolated from flaxseed reduced mammary tumor growth by more than 50%.
Vinorelbine Plus Chemo Promising in Advanced Disease
April 1st 1995SAN ANTONIO--Three different regimens of vinorelbine tartrate (Navelbine) combined with established chemotherapeutic agents led to significant responses in up to 60% of patients with advanced or metastatic breast cancer, including previously treated patients.
Bone Substudy a Part of Tamoxifen Prevention Trial
April 1st 1995PITTSBURGH--A study has begun to determine the effectiveness of tamoxifen (Nolvadex) in preventing osteoporosis in a group of women participating in the Breast Cancer Prevention Trial (BCPT), coordinated by the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Ultrasound Breast Screens Useful in Selected Women
April 1st 1995CHICAGO--Citing findings from radiological studies performed on more than 10,000 women, Paula Gordon, MD, suggests periodic ultrasound examination of the breast in addition to mammography for women at high risk of breast cancer and who have mammographically dense breasts.
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer
April 1st 1995SAN FRANCISCO--Women with breast cancer are at higher risk of developing a second gynecologic cancer than women who do not have the disease, Eva Chalas, MD, reported at a poster session of the Society of Gynecologic Oncologists meeting. Close gynecologic monitoring in the first 3 years after a breast cancer diagnosis is essential, she said.
Breast Cancer Gene Patent Resolved
April 1st 1995WASHINGTON--The National Institutes of Health, University of Utah, and Myriad Genetics, Inc. have resolved issues involving patenting of the BRCA1 breast cancer gene by agreeing that scientists from all three institutions should be named as joint inventors in current patent applications. The agreement also ensures that exclusive, worldwide commercial rights are retained by Myriad and its licensees, Eli Lilly and Company and Hybritech Incorporated.
Studies Explore Optimal Treatment for DCIS, Markers for High Recurrence Risk
April 1st 1995SAN ANTONIO--Searches for high-risk markers may ultimately point the way toward the optimal use of breast-conserving surgery for ductal carcinoma in situ (DCIS); early findings from one study, for example, suggest that a family history of breast cancer may militate against such surgery.
Antman Provides Outlook on Use of High-Dose Chemo
March 1st 1995ATLANTA--In laboratory models, the "highest possible doses of chemotherapy" and a combination of agents are necessary to achieve curative therapy in breast cancer, Karen H. Antman, MD, said at the American Society of Clinical Oncology's (ASCO) Educational Conference. But when treating breast cancer with drugs that damage stem cells, "you may not be able
Identifying the 'Sentinel' Lymph Node May Obviate Need for Total Axillary Dissection
March 1st 1995SAN ANTONIO--Identification of the "sentinel" lymph node can eliminate the need for total axillary node dissection in a substantial number of women with primary breast cancer, Peter D. Beitsch, MD, said at the San Antonio Breast Cancer Symposium.
Breast Examination Center of Harlem Expands Service
March 1st 1995NEW YORK--Gospel singers, ministers, elected officials, breast cancer survivors, and the president and board of Memorial Sloan-Kettering Cancer Center came to Harlem to celebrate, with music and soul food, the expansion of the Breast Examination Center of Harlem, a center that has screened more than 24,000 women for breast cancer since its opening in 1979.
Caveats on Stereotactic Core Biopsy Use
March 1st 1995SAN ANTONIO--Unresolved questions about accuracy and cost should limit the role of stereotactic core biopsy in breast cancer to low-suspicion lesions and a few other specific indications, advised Monica Morrow, MD, associate professor of surgery and director of clinical breast programs, Northwestern University Medical School.
NCAB Hears Reports From Action Plan on Breast Ca, AACR
March 1st 1995WASHINGTON--At its most recent meeting, the National Cancer Advisory Board (NCAB) heard a report on the activities and accomplishments of the National Action Plan on Breast Cancer (NAPBC), as well as reports from two groups concerned about cancer research funding and grant applications.
New Noninvasive Test May Improve Breast Cancer Diagnosis and Reduce Unnecessary Biopsies
February 1st 1995New clinical research shows that a noninvasive test, the Breast Biophysical Examination (BBE), may help physicians more effectively detect breast cancer, as well as identify women who do not have cancer. The research, funded in part by the National Cancer Institute, was presented at the 17th Annual San Antonio Breast Cancer Symposium.
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium
February 1st 1995Tamoxifen (Nolvadex) is widely used in the treatment of breast cancer. It is effective in the management of both early stage and advanced disease. The recent comprehensive meta-analysis of systemic treatment in early breast cancer reported that tamoxifen reduced the annual odds of breast cancer recurrence by 25%, and the risk of death by 16%, compared with patients not treated with tamoxifen [1]. The benefits are even more pronounced in postmenopausal patients, with 29% decreases in recurrence and 20% reduction in the risk of death. The risk of contralateral primary breast cancer is also decreased by approximately 28% in women receiving adjuvant tamoxifen [2]. This has prompted its use in prevention trials; the National Surgical Adjuvant Breast and Bowel Project Prevention trial (NSABP P1) is an ongoing trial randomizing women at high risk for breast cancer to receive tamoxifen or placebo. Tamoxifen's use in otherwise healthy women has brought attention to the few potential toxicities of the drug.
Success of Breast Conserving Surgery Is Not Diminished in Community Setting
January 1st 1995WASHINGTON--The effectiveness of breast conservation surgery, as measured by survival of breast cancer patients, is similar to that of mastectomy in day-to-day medical practice, as well as in randomized clinical studies, according to a report by the General Accounting Office (GAO).
The Breast Implant Controversy: Psychosocial Implications
January 1st 1995In the 1970s, a radical mastectomy represented the sole option for women with breast cancer. Years later, when the issue of quality of life was raised, the era of reconstructive surgery, via silicone gel breast implants--internal prostheses, was born. For
Amifostine Shortens Bone Marrow Recovery Period in Breast Cancer Patients
January 1st 1995A study published in the June 1, 1994 issue of the journal Blood demonstrates that amifostine (Ethyol), a selective cytoprotective agent, significantly shortens the time to bone marrow recovery in breast cancer patients undergoing high-dose
Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer
January 1st 1995PRINCETON, NJ--New approaches in radioimmunotherapy for patients with advanced breast cancer have had promising preliminary results, according to research presented at the Fifth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer.
Purging Grafts Via CD34+ Cell Selection May Show Benefits
January 1st 1995NASHVILLE--Results of a trial of positive-selection purging in breast cancer patients undergoing high-dose chemotherapy/autologous bone marrow or peripheral blood transplantation show that patients who have no evidence of breast cancer in the graft after purging have longer progression-free survival at a median follow-up of 18 months than patients who have persistent evidence of tumor. Purging is performed by selection of CD34+ marrow or peripheral blood progenitor cells (PBPCs).
NIH and Private Industry in Legal Battle over Breast Cancer Gene Patent
January 1st 1995WASHINGTON--The National Institutes of Health (NIH) is disputing the commercial rights to the newly discovered breast cancer gene BRCA1. In a move that could affect how much women pay for screening when such a test becomes available, scientists at the University of Utah and Myriad Genetics, Inc. failed to include NIH as a collaborator when it applied to patent the gene. The NIH has filed a counter application.